GenVec Inc  

(Public, NASDAQ:GNVC)   Watch this stock  
Find more results for GNVC
2.07
-0.10 (-4.61%)
Sep 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.06 - 2.28
52 week 0.73 - 4.25
Open 2.20
Vol / Avg. 98,659.00/40,269.00
Mkt cap 37.48M
P/E     -
Div/yield     -
EPS -0.47
Shares 17.27M
Beta 2.05
Inst. own 33%
Aug 12, 2014
Q2 2014 GenVec Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -1296.12% -272.11%
Operating margin -1299.22% -279.58%
EBITD margin - -274.85%
Return on average assets -39.74% -81.18%
Return on average equity -48.95% -109.18%
Employees 11 -
CDP Score - -

Address

65 West Watkins Mill Road
GAITHERSBURG, MD 20878
United States - Map
+1-240-6320740 (Phone)
+1-240-6320735 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

GenVec, Inc. develops gene-based pharmaceuticals and therapies for the treatment of major medical needs. The Company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates that address needs in the areas of cardiovascular disease, cancer and other therapeutic areas.

Officers and directors

Wayne T. Hockmeyer Ph.D. Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Douglas J. Swirsky President, Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Bryan T. Butman Ph.D. Senior Vice President - Development
Age: 60
Bio & Compensation  - Reuters
Douglas E. Brough Ph.D. Vice President - Head of Research
Age: 58
Bio & Compensation  - Reuters
Zola P. Horovitz Ph.D. Director
Age: 79
Bio & Compensation  - Reuters
Stefan F. Loren Ph.D. Director
Age: 49
Bio & Compensation  - Reuters
William N. Kelley M.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Marc R. Schneebaum Independent Director
Age: 59
Bio & Compensation  - Reuters